$Kiniksa Pharmaceuticals International (KNSA.US)$
Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus?

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Okie, let’s look at the market. As I am very busy recently, my post is a lot slower. But, I am still monitoring the market closely. Today, the posts will be long, and the contents are as below:
i) Current market- $SPDR S&P 500 ETF (SPY.US)$
ii) Oil price
iii) My trade based on stage analysis
i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...

$Kiniksa Pharmaceuticals International (KNSA.US)$ buy more for TP $30